{
    "response": "**Overall Treatment Decision:** Yes\n\n**Specific Treatment Recommendations:**\n\n*   **Treatment:** Intravenous methylprednisolone 1 g daily for 3\u20135 days\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Severe visual acuity loss (6/60) in suspected optic neuritis Accelerates visual recovery First-line for NMOSD/MOG while awaiting antibodies\n\n*   **Treatment:** Proton pump inhibitor while on high-dose steroids\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Gastric protection during IV corticosteroids\n\n*   **Treatment:** Blood glucose monitoring with insulin protocol if needed\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Steroid-induced hyperglycaemia risk History of hyperglycaemia\n\n*   **Treatment:** Urgent neuro-ophthalmology/ophthalmology co-management and visual safety advice\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Severe visual impairment requires joint care Driving/occupational safety\n\n*   **Treatment:** Therapeutic plasma exchange (5 exchanges over 7\u201310 days)\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Escalate if no meaningful improvement within 48\u201372 hours of steroids Indicated if AQP4/MOG positive or profound deficit\n\n*   **Treatment:** Long-term immunotherapy for NMOSD (e.g., rituximab/inebilizumab/satralizumab)\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Begin after confirmation of AQP4-IgG disease Initiate once acute attack stabilises\n\n*   **Treatment:** Multiple sclerosis disease-modifying therapy\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Start only if MS diagnosis established by MRI/CSF demonstrating dissemination in time and space\n\n\ntreatments = [{\"treatment\": \"Intravenous methylprednisolone 1 g daily for 3\\u20135 days\", \"timing\": \"Start Now\", \"reasons\": [\"Severe visual acuity loss (6/60) in suspected optic neuritis\", \"Accelerates visual recovery\", \"First-line for NMOSD/MOG while awaiting antibodies\"]}, {\"treatment\": \"Proton pump inhibitor while on high-dose steroids\", \"timing\": \"Start Now\", \"reasons\": [\"Gastric protection during IV corticosteroids\"]}, {\"treatment\": \"Blood glucose monitoring with insulin protocol if needed\", \"timing\": \"Start Now\", \"reasons\": [\"Steroid-induced hyperglycaemia risk\", \"History of hyperglycaemia\"]}, {\"treatment\": \"Urgent neuro-ophthalmology/ophthalmology co-management and visual safety advice\", \"timing\": \"Start Now\", \"reasons\": [\"Severe visual impairment requires joint care\", \"Driving/occupational safety\"]}, {\"treatment\": \"Therapeutic plasma exchange (5 exchanges over 7\\u201310 days)\", \"timing\": \"Delay\", \"reasons\": [\"Escalate if no meaningful improvement within 48\\u201372 hours of steroids\", \"Indicated if AQP4/MOG positive or profound deficit\"]}, {\"treatment\": \"Long-term immunotherapy for NMOSD (e.g., rituximab/inebilizumab/satralizumab)\", \"timing\": \"Delay\", \"reasons\": [\"Begin after confirmation of AQP4-IgG disease\", \"Initiate once acute attack stabilises\"]}, {\"treatment\": \"Multiple sclerosis disease-modifying therapy\", \"timing\": \"Delay\", \"reasons\": [\"Start only if MS diagnosis established by MRI/CSF demonstrating dissemination in time and space\"]}]"
}